California Governor Newsom inked bill AB 824 and is expected to sign AB 744 this week, both of which will impact healthcare payment models. Companies seeking to manage healthcare costs are actively trying to influence where medications are delivered. New cancer research in triple negative breast
ESMO Conference Updates and More
The European Society of Medical Oncology (ESMO) conference wrapped up this week with many exciting announcements and developments. New studies from Lilly, AstraZeneca, Merck and others showed promise treating lung cancer, thyroid cancer, prostate cancer and more. Hospitals and medical groups are
New House Proposal Would Lift Ban on HHS Negotiating Medicare Drug Prices
The Democrats unveiled their plan to combat rising drug prices. House Leader Nancy Pelosi’s plan would lift the ban on the HHS to allow the secretary to negotiate Medicare drug prices. Pharmaceutical companies would be forced to comply or face stiff penalties. Other top stories this week focus on
States Consider Value-Based Drug Pricing, Committee Investigates Role of Equity Firms in Surprise Billing Problems
In this week’s Innovation Partners’ BioBlog, states consider several models for value-based drug pricing but face significant challenges to move forward with any of them. A House panel is investigating the role that private equity firms may play in surprise patient billing; many of these firms own
New CPT Codes Account for Changing Technology, Cigna Launches New Benefit Solution, More
In this week’s Innovation Partners BioBlog, we feature several stories on the continuing healthcare debate. The President promises a new healthcare plan, but any plan promises to be contentious to some on either side of the aisle. New CPT codes were announced for 2020 that include e-visits and
Medicare Plan Finder; Challenger to Cholesterol-Lowering Drugs; More
The Centers for Medicare and Medicaid Services launched a brand-new, redesigned site to help the 60 million eligible for Part D coverage and Medicare Advantage to comparison shop their plans. New research in cancer offers the potential for breakthroughs in non-small-cell lung cancer. MedCo’s new
Marketing Opportunities in the Pharmaceutical Industry; Legislation Impacting the Health Industry
In this week’s Innovation Partners BioBlog, we take a look at a new report from Accenture Life Sciences which indicates that patients prefer to turn to patient groups rather than pharmaceutical companies for resources and information. This may indicate a potential opportunity for pharmaceutical
Tufts Health Plan/Harvard Pilgrim Merger, Utah Medicaid Expansion Denied, More
Tufts Health Plan and Harvard Pilgrim announced a planned merger, which would make the new as-yet-to-be-named organization a rising competitor to the Partners Health Group, a dominant player in the area. CMS will display the 5-star rating next to plans on the Affordable Care website, a move to make